Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Express Scripts Says Customers Support Removal Of Several Pfizer Products From Formulary

This article was originally published in The Pink Sheet Daily

Executive Summary

Decision to drop Lipitor and Norvasc from its 2006 formulary represents an opportunity for savings without compromising health outcomes, the PBM says.

You may also be interested in...



Express Scripts Sees Rapid Switching to Zocor

The success at switching patients to Zocor ahead of the availability of a generic demonstrates the success of PBMs in driving market share, CEO Paz says.

Express Scripts Sees Rapid Switching to Zocor

The success at switching patients to Zocor ahead of the availability of a generic demonstrates the success of PBMs in driving market share, CEO Paz says.

FDA’s Trigger Policy For Generic Lawsuit Decisions “Facilitates Certainty,” Court Rules

The decision will uphold FDA’s newly created policy, barring a dissenting opinion from the District Court of Appeals.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel